期刊
CLINICAL CANCER RESEARCH
卷 25, 期 7, 页码 2042-2048出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-18-1625
关键词
-
类别
资金
- Neurosurgery Research & Education Foundation
- B*Cured Research Fellowship Grant
- Society for Immunotherapy of Cancer-AstraZeneca Postdoctoral Cancer Immunotherapy in Combination Therapies Clinical Fellowship Award
- [NIH: R01-NS099463]
- [P50-CA190991]
- [P30-CA14236]
- [R01-CA177476]
- [U01-NS090284]
- [R01-NS085412]
- [R25-NS065743]
Glioblastoma (GBM) is a devastating disease with an extremely poor prognosis. Immunotherapy via adoptive cell transfer (ACT), especially with T cells engineered to express chimeric antigen receptors (CAR), represents a particularly promising approach. Despite the recent success of CAR T cells for blood cancers, the question remains whether this powerful anticancer therapy will ultimately work for brain tumors, and whether the primary immunologic challenges in this disease, which include antigenic heterogeneity, immune suppression, and T-cell exhaustion, can be adequately addressed. Here, we contextualize these concepts by reviewing recent developments in ACT for GBM, with a special focus on pioneering clinical trials of CAR T-cell therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据